Convergent Therapeutics: Funding, Investors & Team (Oct 2026)
Convergent Therapeutics is a pharmaceutical company specializing in the development of radiopharmaceutical treatments for prostate cancer. One of their key products, CONV 01-α, is a monoclonal antibody attached to a radioactive alpha particle emitter, designed to target the prostate-specific membrane antigen (PSMA) and deliver radiation directly to cancer cells. This technology was developed by Dr. Neil Bander and licensed to Convergent by Cornell University. CONV 01-α is protected by several patents and, if approved by the FDA, would be the first antibody to deliver a radioisotope specifically to prostate cancer cells and the first cancer treatment to use 225Ac.
Convergent Therapeutics has raised $112M across 2 funding rounds on record, the most recent an undisclosed round of $22.2M announced in Aug 2024.
That round is above the $4.9M median round size for Health Care companies tracked on FundedIQ over the last two years.
Convergent Therapeutics Company Profile and Key Stats
Latest funding round on record: Aug 2024.
Convergent Therapeutics Funding Rounds
Convergent Therapeutics raised $90.0M in a Series A announced in May 2023.
1.3 years later, an undisclosed round of $22.2M was announced in Aug 2024.
Convergent Therapeutics Founders and Leadership Team
Contact details for the Convergent Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Convergent Therapeutics Funding Compared to Other Health Care Startups
Convergent Therapeutics' latest round of $22.2M is above the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Convergent Therapeutics in Health Care and Cambridge
Companies Similar to Convergent Therapeutics
Using technology and the best professionals, Wally, a membership-based dental care service, offers proactive,…
PreciseDx is a unique Cancer Risk Stratification company that offers personalized risk information by…
General Medicine provides a convenient and straightforward way to access top-quality healthcare services with…
Forty million men in the US and over 500 million worldwide suffer from urinary obstruction related to benign…
SedMed provides medical devices that support safer toileting transfers and help prevent falls for individuals…
Aptatek is developing cutting edge technologies for portable disease management devices that will improve…
Flow Medical offers multi-function catheters to aid in the diagnosis and treatment of venous thromboembolic…
Light Wave Dental Management offers management services for high-quality dental offices in Virginia.…
For health care systems and payers focused on improving maternal outcomes and health equity, our product is a…
Tempo Therapeutics creates materials that are designed for regenerative medicine, with a focus on being…
Vibronix was established by Dr. Ji-Xin Cheng and Dr. Pu Wang at Purdue University with the goal of offering…
People with chronic diseases can live their best lives thanks to Vheda Health. We concentrate on three areas…
Convergent Therapeutics Funding FAQs
What does Convergent Therapeutics do?
Convergent Therapeutics is a pharmaceutical company specializing in the development of radiopharmaceutical treatments for prostate cancer. One of their key products, CONV 01-α, is a monoclonal antibody attached to a radioactive alpha particle emitter, designed to target the prostate-specific membrane antigen (PSMA) and deliver radiation directly to cancer cells. This technology was developed by Dr. Neil Bander and licensed to Convergent by Cornell University. CONV 01-α is protected by several patents and, if approved by the FDA, would be the first antibody to deliver a radioisotope specifically to prostate cancer cells and the first cancer treatment to use 225Ac.
How much funding has Convergent Therapeutics raised?
Convergent Therapeutics has raised $112M across 2 rounds on record. The most recent is an undisclosed round of $22.2M announced in Aug 2024.
When did Convergent Therapeutics last raise funding?
Convergent Therapeutics' most recent funding round on record is an undisclosed round of $22.2M, announced in Aug 2024.
Who founded Convergent Therapeutics?
FundedIQ lists Philip Kantoff (Founder) at Convergent Therapeutics.
Where is Convergent Therapeutics headquartered?
Convergent Therapeutics is based in Cambridge, Massachusetts, United States.
How many employees does Convergent Therapeutics have?
Convergent Therapeutics is in the 11-50 employee band.
How does Convergent Therapeutics' funding compare to other Health Care startups?
Convergent Therapeutics' latest round of $22.2M is above the $4.9M median round size for Health Care companies on FundedIQ across 3,659 tracked companies over the last two years.
About FundedIQ's Convergent Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Convergent Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.